Anti-PEDV Spike glycoprotein (RBD) Polyclonal Antibody

Catalog No.

PVV31301

Species reactivity

Porcine epidemic diarrhea virus (strain CV777) (PEDV)

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant PEDV Spike glycoprotein (RBD) (Phe617-Val745).

Tested applications

ELISA: 1:4000-1:8000, WB: 1:1000-1:4000

Target

Spike glycoprotein, S glycoprotein, E2, Peplomer protein, S

Concentration

0.79 mg/ml

Purification

Purified by antigen affinity column.

Accession

Q91AV1

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Designed miniproteins potently inhibit and protect against MERS-CoV., PMID:40450691

A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories., PMID:39772242

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV., PMID:39644492

Isolation and escape mapping of broadly neutralizing antibodies against emerging delta-coronaviruses., PMID:39488210

A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification., PMID:39383863

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals., PMID:39197450

Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans., PMID:39058596

Human coronavirus HKU1 recognition of the TMPRSS2 host receptor., PMID:38964328

Spike deep mutational scanning helps predict success of SARS-CoV-2 clades., PMID:38961298

Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission., PMID:38953636

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines., PMID:38944664

Evidences support that dengue virus can impart broad-spectrum immunity against betacoronaviruses in dengue endemic regions., PMID:38932494

The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study., PMID:38921803

Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans., PMID:38490197

Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity., PMID:38459086

Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus., PMID:37989312

Neutralization, effector function and immune imprinting of Omicron variants., PMID:37648855

Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics., PMID:36503013

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice., PMID:35988541

Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern., PMID:35695453

A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike., PMID:35273217

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy., PMID:35134084

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines., PMID:34619077

COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models., PMID:34547465

Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design., PMID:34267764

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape., PMID:34261126

Tackling COVID-19 with neutralizing monoclonal antibodies., PMID:34087172

Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein., PMID:33909660

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2., PMID:33761326

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies., PMID:33706364

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2., PMID:33160446

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection., PMID:33139569

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies., PMID:32375025

A continuous epitope from transmissible gastroenteritis virus S protein fused to E. coli heat-labile toxin B subunit expressed by attenuated Salmonella induces serum and secretory immunity., PMID:8725098

Document Download

Anti-PEDV Spike glycoprotein (RBD) Polyclonal Antibody.pdf